Drug Profile
Bone marrow mononuclear cell therapy - Beike Biotech
Alternative Names: BM-MNCLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Beike Biotechnology
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Diabetic foot
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetic-foot in China (IM, Injection)
- 31 Oct 2006 Preclinical trials in Diabetic foot in China (IM)